Systematic literature review on the economic, humanistic, and societal burden of heart failure in children and adolescents

Global, regional, and national burdens of heart failure in adolescents and young adults aged 10-24 years from 1990 to 2021: an analysis of data from the Global Burden of Disease Study 2021

Background

Prior studies suggest prevalence of heart failure (HF) has remained steady or progressively decreased over past 30 years in the general population. Whether this favourable trend occurred in adolescents and young adults aged 10-24 years has yet to be elucidated. We aim to identify the trends in the burden of HF in this young population from 1990 to 2021 to inform areas for targeted intervention and prevention efforts.

Methods

We analyzed data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021. The case number and rates per 100,000 population of prevalence and years lived with disability (YLDs) of HF at the global, regional, and national level in the population aged 10-24 years from 1990 to 2021 were reported. In addition, the HF trends by age, sex, and socio-demographic index (SDI) were analyzed. Furthermore, we calculated the average annual percentage changes (AAPC) and identified the year with the most pronounced changes in the trends with the joinpoint regression analysis. In detail, we divided the study population into three age groups: 10-14 years old, 15-19 years old, and 20-24 years old. We also employed the Bayesian age-period-cohort models (BAPC) to predict the future burden of HF up to 2030.

Findings

Globally, the prevalence and YLDs rates of HF among adolescents and young adults in 2021 were 148.1 (95% uncertainty interval [UI]: 118.8-185.7) and 14.4 (9.2-21.2) per 100 000 population, increased from 125.5 (100.0-157.7) and 12.2 (7.8-17.8) in 1990 respectively. Noticeable changes in HF prevalence were found in 1994, 2001, 2004, 2010, and 2018. Regionally, East Asia had the most pronounced increase in HF prevalence rate (AAPC = 1.35 [1.28-1.43]) and YLDs rate (AAPC = 1.32 [1.27-1.38]), while the highest HF prevalence rates per 100,000 population were observed in High-income North America (232 [185.4-292]). The prevalence and YLDs of HF increased in most countries except Australia, Canada, and Spain. The largest increase in HF prevalence rate was observed in China (AAPC = 1.39 [1.31-1.48]). By SDI quintile, the middle-SDI quintile countries had the largest increase in prevalence and YLDs rates. By sex, males had a higher prevalence rate per 100,000 population than females (158.0 [95% UI: 126.7-198.9] vs 137.6 [95% UI: 110.0-172.2]) in 2021. Among three age groups, the largest increase in HF prevalence from 1990 to 2021 was found in individuals aged 20-24 years (AAPC = 0.61 [0.6-0.61]). Among all causes of HF, cardiomyopathy and myocarditis accounted for the highest proportion (32.7%) of prevalence cases of HF in 2021, followed by congenital birth defects (27.3%), and rheumatic heart disease (23.8%). The BAPC analysis predicted that the cases of HF prevalence and YLDs would show a rising trend from 2022 to 2030.

Interpretation

The burden of HF in adolescents and young adults aged 10-24 years was still increasing globally, which may be obscured by the burden trend of general population. According to different underlying causes of HF, both high-income countries and low- and middle-income countries need to better prevent HF in adolescents and young adults.

Funding

National Natural Science Foundation of China (grant 81900452) and Training Fund for Open Projects at Clinical Institutes and Departments of Capital Medical University (grant CCMU2022ZKYXY003).

Epidemiology of Pediatric Heart Failure in the USA-a 15-Year Multi-Institutional Study

The epidemiology of pediatric heart failure (HF) has been characterized for congenital heart disease (CHD) and cardiomyopathies (CM), but the impact of CM associated with CHD has not been studied. This study aims to describe the characteristics and outcomes of inpatient pediatric HF patients with CHD, CM, and CHD with CM (CHD + CM) across the USA. We included all HF patients with CM diagnoses with and without CHD using ICD 9/10 codes ≤ 19 years old from January 2004 to September 2019 using the Pediatric Health Information System database. We identified 67,349 unique patients ≤ 19 years old with HF, of which 87% had CHD, 7% had CHD + CM, and 6% had CM. Pediatric HF admissions increased significantly from 2004 to 2018 with an associated increase in extracorporeal circulatory support (ECLS) use. Heart transplantation (HTX) increased only in the CHD and CHD + CM groups. CHD patients required less ECLS with and without HTX; however, they had significantly higher inpatient mortality after those procedures than the other groups (p < 0.001). CM patients were older (median 115 months) and had the lowest inpatient mortality after HTX with and without ECLS (p < 0.05). CHD + CM showed the highest overall inpatient mortality (15%), and cumulative hospital billed charges (median US$ 541,374), all p < 0.001. Pediatric HF admissions have increased from 2004 to 2018. ECLS use and HTX have expanded in this population, with an associated decrease in inpatient mortality in the CHD and CM groups. CHD + CM patients are a growing population with the highest inpatient mortality.